FIELD: immunology.
SUBSTANCE: disclosed is a CD19-specific chimeric antigen receptor. Also, a polynucleotide, an expression vector created by genetic engineering of T-lymphocytes are considered. What is also described is a method for creating T-lymphocyte, methods of treating B-cell lymphoma or leukemia.
EFFECT: present invention can find further application in therapy of B-cell lymphoma and leukemia.
26 cl, 6 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND WAYS OF USE THEREOF | 2020 |
|
RU2816370C2 |
| CELL | 2014 |
|
RU2717984C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
| CELL | 2014 |
|
RU2732236C2 |
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| T-CELLS MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING CS1 | 2015 |
|
RU2727451C2 |
| CHIMERIC ANTIGEN RECEPTORS AIMED AT PSCA | 2016 |
|
RU2759879C2 |
| IMMUNOTHERAPY CELLS DESIGNED FOR TARGETING ANTIGEN PRESENT SIMULTANEOUSLY ON IMMUNE CELLS AND ON PATHOLOGICAL CELLS | 2015 |
|
RU2714258C2 |
| INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
